Jamil Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jamil Shah has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Abdulrahman Atasi
Department of Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, NY 11212, USA
3 shared publications - Jamal Christopher Perry
Department of Cardiology, University of Cincinnati, Cincinnati, OH 45219, USA, USA
3 shared publications Kibwey Peterkin
Department of Palliative Care, Yale University, New Haven, CT 06511, USA
3 shared publications- Omar Aaron Oudit
Department of Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, NY 11212, USA
3 shared publications - Temitayo Adebowale
Department of Biomedical Science, Columbia Irving Medical Center, New York, NY 10032, USA
3 shared publications - Chidiebele E. Omaliko
Department of Gastroenterology, Brookdale University Hospital Medical Center, Brooklyn, NY 11212, USA
2 shared publications
Latest Publications
- Open Access
- 18 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3894
The Impact of Aspirin Use on In-Hospital Outcomes and Metastatic Disease in Colorectal Cancer: An Evaluation of the National Inpatient Sample
Background: Aspirin, initially recognized for its anti-inflammatory, antipyretic and analgesic properties, holds a prominent role in the treatment of cardiovascular disease. The utility of aspirin in cancer therapeutics has been explored and stratified into COX-dependent and -independent mechanisms. COX2 gene expression has been demonstrated to be significantly upregulated in colorectal cancer and various other gastrointestinal malignancies including pancreatic, esophageal, and gastric cancer. This study investigates the relationship of aspirin use and outcomes in patients with colorectal cancer. Methods: The Nationwide Inpatient Sample (NIS) database from 2017 to 2022 was analyzed for patients age > 18 who were hospitalized for colorectal cancer and its decompensations using ICD-10 diagnostic codes. These patients were further stratified based on the long-term use of aspirin. The principal outcome of this investigation are the odds of in-hospital mortality, with secondary outcomes including odds of pulmonary embolism, portal vein thrombosis, acute kidney injury, septic shock, requiring an ICU level of care and odds of hepatic, pulmonary, gastrointestinal and peritoneal or retroperitoneal metastatic disease. Multivariate logistic regression accounting for hospital and patient characteristics was implemented for analysis, with the Charlson Comorbidity Index used to adjust for coexisting comorbidity burden; a p-value (p) of p value < 0.001 95% CI (confidence interval): 0.460–0.617. Patients with aspirin use also demonstrated significantly reduced odds of adverse outcomes and gastrointestinal, hepatic, pulmonary and retroperitoneal/peritoneal metastasis; (aOR 0.606, 95% CI: 0.564–0.653, p < 0.001), (aOR 0.628, 95% CI: 0.582–0.678, p < 0.001), (aOR 0.676, 95% CI: 0.605–0.755, p < 0.001) and (aOR 0.751, 95% CI: 0.685–0.825, p < 0.001) respectively. Conclusions: In recent years, there has been an alarming increase in incidence of colorectal cancer, particularly amongst younger individuals with increased associated mortality. This mortality increase, albeit alarming, is a driving force for treatment innovation with continual examination of our repertoire of medications for possible repurposed applications. COX2-mediated signaling serves as a key promotor of tumorigenic molecular signaling that directly contributes to tumor cell proliferation, angiogenesis and metastasis in colorectal cancer. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced odds of in-hospital mortality. Aspirin use is also associated with significantly reduced odds of developing metastatic disease to the liver, gastrointestinal system, lungs and peritoneum in patients with colorectal cancer. These findings convey that aspirin use reduces the likelihood of in-hospital mortality, major comorbid conditions and of developing metastatic disease as compared to those who do not use aspirin.
- 18 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3894
Open AccessThe Impact of Aspirin Use on In-Hospital Outcomes and Metastatic Disease in Colorectal Cancer: An Evaluation of the National Inpatient Sample
Background: Aspirin, initially recognized for its anti-inflammatory, antipyretic and analgesic properties, holds a prominent role in the treatment of cardiovascular disease. The utility of aspirin in cancer therapeutics has been explored and stratified into COX-dependent and -independent mechanisms. COX2 gene expression has been demonstrated to be significantly upregulated in colorectal cancer and various other gastrointestinal malignancies including pancreatic, esophageal, and gastric cancer. This study investigates the relationship of aspirin use and outcomes in patients with colorectal cancer. Methods: The Nationwide Inpatient Sample (NIS) database from 2017 to 2022 was analyzed for patients age > 18 who were hospitalized for colorectal cancer and its decompensations using ICD-10 diagnostic codes. These patients were further stratified based on the long-term use of aspirin. The principal outcome of this investigation are the odds of in-hospital mortality, with secondary outcomes including odds of pulmonary embolism, portal vein thrombosis, acute kidney injury, septic shock, requiring an ICU level of care and odds of hepatic, pulmonary, gastrointestinal and peritoneal or retroperitoneal metastatic disease. Multivariate logistic regression accounting for hospital and patient characteristics was implemented for analysis, with the Charlson Comorbidity Index used to adjust for coexisting comorbidity burden; a p-value (p) of p value < 0.001 95% CI (confidence interval): 0.460–0.617. Patients with aspirin use also demonstrated significantly reduced odds of adverse outcomes and gastrointestinal, hepatic, pulmonary and retroperitoneal/peritoneal metastasis; (aOR 0.606, 95% CI: 0.564–0.653, p < 0.001), (aOR 0.628, 95% CI: 0.582–0.678, p < 0.001), (aOR 0.676, 95% CI: 0.605–0.755, p < 0.001) and (aOR 0.751, 95% CI: 0.685–0.825, p < 0.001) respectively. Conclusions: In recent years, there has been an alarming increase in incidence of colorectal cancer, particularly amongst younger individuals with increased associated mortality. This mortality increase, albeit alarming, is a driving force for treatment innovation with continual examination of our repertoire of medications for possible repurposed applications. COX2-mediated signaling serves as a key promotor of tumorigenic molecular signaling that directly contributes to tumor cell proliferation, angiogenesis and metastasis in colorectal cancer. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced odds of in-hospital mortality. Aspirin use is also associated with significantly reduced odds of developing metastatic disease to the liver, gastrointestinal system, lungs and peritoneum in patients with colorectal cancer. These findings convey that aspirin use reduces the likelihood of in-hospital mortality, major comorbid conditions and of developing metastatic disease as compared to those who do not use aspirin.
- Open Access
- 15 April 2026
- Published by MDPI AG in Preprints.org
The Protective Effects of Aspirin Use from Adverse In Hospital Outcomes and Metastatic Disease in Colorectal Cancer: An Evaluation of the National Inpatient Sample
Introduction Aspirin initially recognized for its anti-inflammatory, antipyretic and analgesic properties hold a prominent role in the treatment of cardiovascular disease. The utility of aspirin in cancer therapeutics has been explored and stratified into COX dependent and independent mechanisms. COX2 gene expression has been demonstrated to be significantly upregulated in colorectal cancer and various other gastrointestinal malignancies including pancreatic, esophageal, and gastric cancer. This study investigates the relationship of aspirin use and outcomes in patients with colorectal cancer. Methodology The Nationwide Inpatient Sample (NIS) database from 2017 to 2022 was analyzed for patients age >18 who were hospitalized for colorectal cancer and its decompensations using ICD-10 diagnostic codes. These patients were further stratified based on the long term use of aspirin. The principal outcome of this investigation is in-hospital mortality, with secondary outcomes including rates of pulmonary embolism, portal vein thrombosis, acute kidney injury and need for renal replacement therapy, septic shock and rates of hepatic, pulmonary, gastrointestinal and peritoneal or retroperitoneal metastatic disease. Multivariate logistic regression accounting for hospital and patient characteristics was implemented for analysis, with the Charlson Comorbidity Index used to adjust for coexisting comorbidity burden; a p-value (p) of Results In our analysis of the NIS, 569,306 patients were identified with colorectal cancer and 11.7% (66,608) of this population were identified with long term use of aspirin. Aspirin use was identified to have a significantly reduced odds of in-patient mortality (adjusted odds ratio) [aOR] 0.530, p value Conclusion In recent years there has been an alarming increase in incidence of colorectal cancer, particularly amongst younger individuals with increased associated mortality. This mortality increase, albeit alarming, is a driving force for treatment innovation with continual examination of our repertoire of medications for possible repurposed applications. COX2 mediated signaling serves as a key promotor of tumorigenic molecular signaling that directly contribute to tumor cell proliferation, angiogenesis and metastasis in colorectal cancer. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced risk of in-hospital mortality. Aspirin use is also linked to a significant reduction in odds of developing metastatic disease to the liver, gastrointestinal system, lungs and peritoneum in patients with colorectal cancer. These findings reveal that aspirin exerts shielding effects against in-hospital mortality and protects patients with colorectal cancer from the development of major comorbid conditions and metastatic disease as compared to those who do not use aspirin.
- 15 April 2026
- Published by MDPI AG in Preprints.org
Open AccessThe Protective Effects of Aspirin Use from Adverse In Hospital Outcomes and Metastatic Disease in Colorectal Cancer: An Evaluation of the National Inpatient Sample
Introduction Aspirin initially recognized for its anti-inflammatory, antipyretic and analgesic properties hold a prominent role in the treatment of cardiovascular disease. The utility of aspirin in cancer therapeutics has been explored and stratified into COX dependent and independent mechanisms. COX2 gene expression has been demonstrated to be significantly upregulated in colorectal cancer and various other gastrointestinal malignancies including pancreatic, esophageal, and gastric cancer. This study investigates the relationship of aspirin use and outcomes in patients with colorectal cancer. Methodology The Nationwide Inpatient Sample (NIS) database from 2017 to 2022 was analyzed for patients age >18 who were hospitalized for colorectal cancer and its decompensations using ICD-10 diagnostic codes. These patients were further stratified based on the long term use of aspirin. The principal outcome of this investigation is in-hospital mortality, with secondary outcomes including rates of pulmonary embolism, portal vein thrombosis, acute kidney injury and need for renal replacement therapy, septic shock and rates of hepatic, pulmonary, gastrointestinal and peritoneal or retroperitoneal metastatic disease. Multivariate logistic regression accounting for hospital and patient characteristics was implemented for analysis, with the Charlson Comorbidity Index used to adjust for coexisting comorbidity burden; a p-value (p) of Results In our analysis of the NIS, 569,306 patients were identified with colorectal cancer and 11.7% (66,608) of this population were identified with long term use of aspirin. Aspirin use was identified to have a significantly reduced odds of in-patient mortality (adjusted odds ratio) [aOR] 0.530, p value Conclusion In recent years there has been an alarming increase in incidence of colorectal cancer, particularly amongst younger individuals with increased associated mortality. This mortality increase, albeit alarming, is a driving force for treatment innovation with continual examination of our repertoire of medications for possible repurposed applications. COX2 mediated signaling serves as a key promotor of tumorigenic molecular signaling that directly contribute to tumor cell proliferation, angiogenesis and metastasis in colorectal cancer. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced risk of in-hospital mortality. Aspirin use is also linked to a significant reduction in odds of developing metastatic disease to the liver, gastrointestinal system, lungs and peritoneum in patients with colorectal cancer. These findings reveal that aspirin exerts shielding effects against in-hospital mortality and protects patients with colorectal cancer from the development of major comorbid conditions and metastatic disease as compared to those who do not use aspirin.
- Open Access
- 10 April 2026
- Published by MDPI AG in Preprints.org
Shielding Effects of Aspirin Use from Adverse in Hospital Outcomes in Non-Metastatic Pancreatic Cancer: An Evaluation of the National Inpatient Sample
Aspirin initially recognized for its anti-inflammatory, antipyretic and analgesic properties hold a prominent role in the treatment of cardiovascular disease. The utility of aspirin in cancer therapeutics has been studied by several groups and stratified into COX dependent and independent mechanisms. COX2 gene expression was significantly increased in colorectal cancer and various other gastrointestinal malignancies; pancreatic, esophageal and gastric cancer. Our study investigates the relationship of aspirin use and outcomes in patients with non metastatic pancreatic cancer. Methodology The Nationwide Inpatient Sample, NIS, database from 2017 to 2022 was analyzed for patients age >18 who were hospitalized for non metastatic pancreatic cancer and its decompensations using ICD-10 diagnostic codes. These patients were partitioned based on their use of aspirin. The principal outcome of this investigation is in-hospital mortality, with secondary outcomes including rates of. Multivariate logistic regression was applied to the outcomes, and the Charlson Comorbidity Index was used to adjust for confounders. A p-value (pv) of <0.05 was considered statistically significant. Results In our analysis of the NIS, 139,579 patients were identified with non-metastatic pancreatic cancer and 19,475 patients (13.9%) were identified with aspirin use and 120,177 patients (86.1%) with no aspirin use. Aspirin use was identified to have a significantly reduced odds of in-patient mortality (adjusted odds ratio) (aOR) 0.531; p value <0.001 95% CI (confidence interval): 0.419 – 0.673. Patients with aspirin use also demonstrated significantly reduced odds of developing a pulmonary embolism, portal vein thrombosis, acute kidney injury, renal replacment therapy, septic shock, of requiring an ICU level of care. Conclusion The mortality increase in pancreatic cancer mortality, albeit alarming, serves as a driving force for treatment innovation with continual examination of current treatments and our repertoire of medications for possible repurposed applications. COX2 mediated signaling serves as a key promotor of tumorigenic molecular signaling that directly contribute to tumor cell proliferation, angiogenesis and metastasis in pancreatic cancer. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced risk of in-hospital mortality. Aspirin use is also linked to a significant reduction in odds of developing non metastatic pancreatic cancer. Our findings support that aspirin exerts shielding effects against in-hospital mortality and protects patients with non metastatic pancreatic cancer from the development of major in hospital comorbidities as compared to those who do not use aspirin.
- 10 April 2026
- Published by MDPI AG in Preprints.org
Open AccessShielding Effects of Aspirin Use from Adverse in Hospital Outcomes in Non-Metastatic Pancreatic Cancer: An Evaluation of the National Inpatient Sample
Aspirin initially recognized for its anti-inflammatory, antipyretic and analgesic properties hold a prominent role in the treatment of cardiovascular disease. The utility of aspirin in cancer therapeutics has been studied by several groups and stratified into COX dependent and independent mechanisms. COX2 gene expression was significantly increased in colorectal cancer and various other gastrointestinal malignancies; pancreatic, esophageal and gastric cancer. Our study investigates the relationship of aspirin use and outcomes in patients with non metastatic pancreatic cancer. Methodology The Nationwide Inpatient Sample, NIS, database from 2017 to 2022 was analyzed for patients age >18 who were hospitalized for non metastatic pancreatic cancer and its decompensations using ICD-10 diagnostic codes. These patients were partitioned based on their use of aspirin. The principal outcome of this investigation is in-hospital mortality, with secondary outcomes including rates of. Multivariate logistic regression was applied to the outcomes, and the Charlson Comorbidity Index was used to adjust for confounders. A p-value (pv) of <0.05 was considered statistically significant. Results In our analysis of the NIS, 139,579 patients were identified with non-metastatic pancreatic cancer and 19,475 patients (13.9%) were identified with aspirin use and 120,177 patients (86.1%) with no aspirin use. Aspirin use was identified to have a significantly reduced odds of in-patient mortality (adjusted odds ratio) (aOR) 0.531; p value <0.001 95% CI (confidence interval): 0.419 – 0.673. Patients with aspirin use also demonstrated significantly reduced odds of developing a pulmonary embolism, portal vein thrombosis, acute kidney injury, renal replacment therapy, septic shock, of requiring an ICU level of care. Conclusion The mortality increase in pancreatic cancer mortality, albeit alarming, serves as a driving force for treatment innovation with continual examination of current treatments and our repertoire of medications for possible repurposed applications. COX2 mediated signaling serves as a key promotor of tumorigenic molecular signaling that directly contribute to tumor cell proliferation, angiogenesis and metastasis in pancreatic cancer. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced risk of in-hospital mortality. Aspirin use is also linked to a significant reduction in odds of developing non metastatic pancreatic cancer. Our findings support that aspirin exerts shielding effects against in-hospital mortality and protects patients with non metastatic pancreatic cancer from the development of major in hospital comorbidities as compared to those who do not use aspirin.